Blue Owl Capital Holdings LP Janux Therapeutics, Inc. Transaction History
Blue Owl Capital Holdings LP
- $303 Million
- Q3 2024
A detailed history of Blue Owl Capital Holdings LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Blue Owl Capital Holdings LP holds 80,000 shares of JANX stock, worth $3.48 Million. This represents 1.2% of its overall portfolio holdings.
Number of Shares
80,000
Previous 40,000
100.0%
Holding current value
$3.48 Million
Previous $1.68 Million
116.96%
% of portfolio
1.2%
Previous 0.7%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
169Shares Held
37.7MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$399 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$110 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$104 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$102 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$90.2 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.81B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...